Bavarian Nordic A/S
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
20
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Production of IFN-lambda by conventional dendritic cells (US 9,090,897) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 4 fees due Feb 15 to 18, 2027 · next Feb 15
- 1 fee due Mar 12, 2027The maintenance fee for Cassette Encoding a Fpv/Brachyury Fusion Protein (US 11,753,652) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements (US 9,163,237) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Recombinant modified vaccinia virus Ankara influenza vaccine (US 9,173,933) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin (US 10,512,684) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (US 10,532,094) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 2 fees due Sep 3 to 5, 2027 · next Sep 3
Recent changes
- 2 of the patents on this record were granted since Aug 21, 2026
- Oct 13 US 12,758,628 Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
- Sep 29 US 12,746,282 A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
- 2 terms have ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,335,364 | Modified Vaccinia Ankara virus variant In force · USPTO record | In force | USPTO record | |
| US 8,313,740 | Methods for treating cancer with a recombinant MVA expressing HER-2 In force · USPTO record | In force | USPTO record | |
| US 8,003,363 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines In force · USPTO record | In force | USPTO record | |
| US 8,003,364 | Purification of vaccinia viruses using hydrophobic interaction chromatography In force · USPTO record | In force | USPTO record | |
| US 8,012,738 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines In force · USPTO record | In force | USPTO record | |
| US 8,163,531 | Purification of vaccinia viruses using hydrophobic interaction chromatography In force · USPTO record | In force | USPTO record | |
| US 8,211,686 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines In force · USPTO record | In force | USPTO record | |
| US 8,415,132 | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines In force · USPTO record | In force | USPTO record | |
| US 8,470,578 | Purification of vaccinia viruses using hydrophobic interaction chromatography In force · USPTO record | In force | USPTO record | |
| US 9,109,201 | Purification of vaccinia viruses using hydrophobic interaction chromatography In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 59: 3 patents in force now held by others · 38 lapsed for an unpaid fee · 50 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 20 no status recorded